SCHEMBL2216522

SCHEMBL2216522

O=C(c1ccc2c(CN3CCC(N4CCCCC4)CC3)c[nH]c2c1)N1CCCCCC1

nearest known ligand 0.72

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 10/20 0.72
L3MBTL3 Q96JM7 8/20 0.56
L3MBTL1 Q9Y468 7/20 0.56
MBTD1 Q05BQ5 5/20 0.56
LMNA P02545 1/20 0.50
TP53BP1 Q12888 1/20 0.50
L3MBTL4 Q8NA19 1/20 0.50
ALDH1A1 P00352 1/20 0.50
TP53 P04637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2216181 0.94 HRH3 (0.79) HRH3L3MBTL3L3MBTL1MBTD1LMNA
SCHEMBL2222442 0.93 HRH3 (0.67) HRH3L3MBTL3L3MBTL1MBTD1LMNA
SCHEMBL2220512 0.93 HRH3 (0.84) HRH3L3MBTL3L3MBTL1MBTD1
SCHEMBL2218323 0.93 HRH3 (0.75) HRH3L3MBTL3L3MBTL1MBTD1LMNA
SCHEMBL2217678 0.93 HRH3 (0.84) HRH3LMNAALDH1A1TP53
SCHEMBL2218325 0.93 HRH3 (0.80) HRH3L3MBTL3L3MBTL1LMNAALDH1A1
SCHEMBL2219371 0.93 HRH3 (0.84) HRH3LMNAALDH1A1TP53
SCHEMBL2218822 0.92 HRH3 (0.66) HRH3L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL2217672 0.92 HRH3 (0.79) HRH3L3MBTL3L3MBTL1MBTD1LMNA
SCHEMBL2218471 0.90 HRH3 (0.63) HRH3L3MBTL3L3MBTL1MBTD1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178062-A1 INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2011-07-21 US claimed
US-20110178062-A1 INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2011-07-21 US disclosed
US-20110178062-A1 INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2011-07-21 US disclosed
US-20110178062-A1 INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2011-07-21 US disclosed
WO-2008109333-A1 INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178062-A1 INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR HRH3, HRH4, HRH1 HRH3 1/4885L3MBTL3 2114/4885L3MBTL1 1896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.